DBV Technologies (DBVT) announced the appointment of Kevin Trapp as chief commercial officer, effective immediately. In his role, Trapp will report directly to Daniel Tasse, CEO, as a member of the executive team and will lead all aspects of global commercial strategy and execution for the Viaskin Peanut patch. DBV expects to submit a biologics license application submission for children 4-7 years-old living with peanut allergy in the first half of 2026, followed by an anticipated BLA submission for 1-3 year-olds in the second half of the year.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DBVT:
- DBV Technologies Appoints Dr. Philina Lee to Board
- DBV Technologies price target raised to $20 from $16 at H.C. Wainwright
- DBV Technologies Reports Q3 2025 Financial Results
- DBV Technologies reports Q3 GAAP EPS (24c), consensus (29c)
- DBV Technologies S.A. – American Depositary Shares (DBVT) Q3 Earnings Cheat Sheet